European S3‐Guideline on the systemic treatment of psoriasis vulgaris – Update Apremilast and Secukinumab – EDF in cooperation with EADV and IPC

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the European Academy of Dermatology and Venereology 2017-12, Vol.31 (12), p.1951-1963
Hauptverfasser:	Nast, A., Spuls, P.I., Kraaij, G., Gisondi, P., Paul, C., Ormerod, A.D., Saiag, P., Smith, C.H., Dauden, E., Jong, E.M., Feist, E., Jobling, R., Maccarone, M., Mrowietz, U., Papp, K.A., Reich, K., Rosumeck, S., Talme, T., Thio, H.B., Kerkhof, P., Werner, R.N., Dressler, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Dermatologic Agents - adverse effects Dermatologic Agents - therapeutic use Humans Psoriasis - drug therapy Thalidomide - adverse effects Thalidomide - analogs & derivatives Thalidomide - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!